JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kem, W. R.
Right arrow Articles by Lingle, C. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kem, W. R.
Right arrow Articles by Lingle, C. J.

Vol. 283, Issue 3, 979-992, 1997

Anabaseine Is a Potent Agonist on Muscle and Neuronal Alpha-Bungarotoxin-Sensitive Nicotinic Receptors1

William R. Kem, Vladimir M. Mahnir, Roger L. Papke and Christopher J. Lingle

Department of Pharmacology and Therapeutics (W.R.K., V.M.M., R.L.P.), College of Medicine, University of Florida, Gainesville, Florida and Anesthesia Research Unit (C.J.L.), Department of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri

We assessed the pharmacological activity of anabaseine, a toxin found in certain animal venoms, relative to nicotine and anabasine on a variety of vertebrate nicotinic receptors, using cultured cells, the Xenopus oocyte expression system, contractility assays with skeletal and smooth muscle strips containing nicotinic receptors and in vivo rat prostration assay involving direct injection into the lateral ventricle of the brain. Anabaseine stimulated every subtype of nicotinic receptor that was tested. It was the most potent frog skeletal muscle nicotinic receptor agonist. At higher concentrations it also blocked the BC3H1 (adult mouse) muscle type receptor ion channel. The affinities of the three nicotinoid compounds for rat brain membrane alpha-bungarotoxin binding sites and their potencies for stimulating Xenopus oocyte homomeric alpha7 receptors, expressed in terms of their active monocation concentrations, displayed the same rank order, anabaseine>anabasine> nicotine. Although the maximum currents generated by anabaseine and anabasine at alpha7 receptors were equivalent to that of acetylcholine, the maximum response to nicotine was only about 65% of the acetylcholine response. At alpha4-beta2 receptors the affinities and apparent efficacies of anabaseine and anabasine were much less than that of nicotine. Anabaseine, nicotine and anabasine were nearly equipotent on sympathetic (PC12) receptors, although parasympathetic (myenteric plexus) receptors were much more sensitive to anabaseine and nicotine but less sensitive to anabasine. These differences suggest that there may be different subunit combinations in these two autonomic nicotinic receptors. The preferential interactions of anabaseine, anabasine and nicotine with different receptor subtypes provides molecular clues that should be helpful in the design of selective nicotinic agonists.

0022-3565/97/2833-0979$03.00/0
Copyright © 1997 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
R. L. Papke, W. R. Kem, F. Soti, G. Y. Lopez-Hernandez, and N. A. Horenstein
Activation and Desensitization of Nicotinic {alpha}7-type Acetylcholine Receptors by Benzylidene Anabaseines and Nicotine
J. Pharmacol. Exp. Ther., May 1, 2009; 329(2): 791 - 807.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
R. Freedman, A. Olincy, R. W. Buchanan, J. G. Harris, J. M. Gold, L. Johnson, D. Allensworth, A. Guzman-Bonilla, B. Clement, M. P. Ball, et al.
Initial Phase 2 Trial of a Nicotinic Agonist in Schizophrenia
Am J Psychiatry, August 1, 2008; 165(8): 1040 - 1047.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
N. A. Horenstein, T. J. McCormack, C. Stokes, K. Ren, and R. L. Papke
Reversal of Agonist Selectivity by Mutations of Conserved Amino Acids in the Binding Site of Nicotinic Acetylcholine Receptors
J. Biol. Chem., February 23, 2007; 282(8): 5899 - 5909.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
R. Zhang, N. A. White, F. S. Soti, W. R. Kem, and T. K. Machu
N-Terminal Domains in Mouse and Human 5-Hydroxytryptamine3A Receptors Confer Partial Agonist and Antagonist Properties to Benzylidene Analogs of Anabaseine
J. Pharmacol. Exp. Ther., June 1, 2006; 317(3): 1276 - 1284.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
D. Rayes, G. Spitzmaul, S. M. Sine, and C. Bouzat
Single-Channel Kinetic Analysis of Chimeric {alpha}7-5HT3A Receptors
Mol. Pharmacol., November 1, 2005; 68(5): 1475 - 1483.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
W. R. Kem, V. M. Mahnir, L. Prokai, R. L. Papke, X. Cao, S. LeFrancois, K. Wildeboer, K. Prokai-Tatrai, J. Porter-Papke, and F. Soti
Hydroxy Metabolites of the Alzheimer's Drug Candidate 3-[(2,4-Dimethoxy)Benzylidene]-Anabaseine Dihydrochloride (GTS-21): Their Molecular Properties, Interactions with Brain Nicotinic Receptors, and Brain Penetration
Mol. Pharmacol., January 1, 2004; 65(1): 56 - 67.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
T. K. Machu, M. E. Hamilton, T. F. Frye, C. L. Shanklin, M. C. Harris, H. Sun, T. E. Tenner Jr., F. S. Soti, and W. R. Kem
Benzylidene Analogs of Anabaseine Display Partial Agonist and Antagonist Properties at the Mouse 5-Hydroxytryptamine3A Receptor
J. Pharmacol. Exp. Ther., December 1, 2001; 299(3): 1112 - 1119.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
R. W. Vazquez and R. E. Oswald
Identification of a New Amino Acid Residue Capable of Modulating Agonist Efficacy at the Homomeric Nicotinic Acetylcholine Receptor, alpha 7
Mol. Pharmacol., January 1, 1999; 55(1): 1 - 7.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics.